MBD5 wt Allele clinical trials
23 active trials name this biomarker in their eligibility criteria. Describe your situation to see which ones you may be eligible for.
- Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
- A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia
- Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
- Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD
- Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
- Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)
- Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
- Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
- A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- Mosunetuzumab for CLL MRD Clearance
- Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
- A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
- Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
- UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1
- The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma
- Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
- Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
- Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
- CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
- FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia
- KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that name “MBD5 wt Allele” in their eligibility criteria, at any level. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.